Axtria Thought Leadership
Executive insights and perspectives on the Life Sciences industry
White Paper
Pricing and Market Effects of Biosimilar Entry in the US
This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...
White Paper
The Importance of Governance in Your Incentive Compensation Program
In this white paper, we address the importance of IC Governance, its team make up, roles and responsibilities. We also go into the details of governing best practices towards plan ...
White Paper
Designing Incentive Compensation Plans for Specialty Products
The focus of this white paper is to highlight key challenges in designing IC plans for promoting specialty drugs by a pharmaceutical sales force and recommended best practices when ...
White Paper
Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues
The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...
Industry Survey
State Of Commercial Excellence 2017 – Part 1
Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...
White Paper
Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?
The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...
White Paper
Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies
President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...
Blog
Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics
The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...
White Paper
Make US Pharma Great Again!? – Part 2
Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...
